Trial Profile

An Open-Label Extension and Safety Monitoring Study of Patients with Symptomatic Transthyretin Cardiomyopathy Who Have Completed the Phase II Study AG10-201

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 17 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Acoramidis (Primary)
Indications Amyloidosis; Cardiomyopathies
Focus Adverse reactions
Sponsors BridgeBio Pharma; Eidos Therapeutics

Most Recent Events

01 Feb 2023 Planned End Date changed from 1 Jul 2023 to 1 Jul 2027.
01 Feb 2023 Planned primary completion date changed from 1 Jul 2023 to 1 Jul 2027.
04 Apr 2022 Results (As of August 9, 2021; n=31) presented at the 71st Annual Scientific Session of the American College of Cardiology.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com